| Description | The human neutralizing antibody 002-S21F2 specifically binds Spike S1 of SARS-CoV-2. It bounds with similar affinities to all tested SARS-CoV-2 variant spike proteins. It potently neutralizes live viral isolates of SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta, and Omicron sublineages. This product has been tested by Enzyme-linked immunosorbent assay, Bio-layer interferometry and Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Cross Reactivity | Alpha, Beta, Gamma, Delta, Omicron sublineages (BA.1, BA.2, BA.2.12.1, BA.4, and BA.5) |
| Epitope | It binds to the outer face of the RBD that is accessible in both "down" and "up" conformations and is outside the ACE2-binding motif. |
| Neutralization Mechanism | The antibody targets a conformationally non-ACE2 binding conserved RBD epitope. |
| IC50 | 0.05 μg/mL (WA.1) 0.05 μg/mL (Alpha) 0.02 μg/mL (Beta) 0.03 μg/mL (Gamma) 0.03 μg/mL (Delta) 0.05 μg/mL (Omicron BA.1) 0.04 μg/mL (Omicron BA.2) 0.12 μg/mL (Omicron BA.2.12.1) 0.13 μg/mL (Omicron BA.4) 0.13 μg/mL (Omicron BA.5) |
| Affinity | KD = 0.16 nM (WA.1) KD = 0.16 nM (Alpha) KD = 0.16 nM (Beta) KD = 0.17 nM (Gamma) KD = 0.17 nM (Delta) KD = 0.22 nM (Omicron BA.1) |
| Isotype | Human IgG |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | ELISA: Three-fold serially diluted purified mAb was added to the plates and incubated at room temperature for 1 hour. Bio-layer interferometry (BLI): 5 μg/mL concentration of 002-S21F2 was captured on a protein A sensor, and its binding kinetics were tested with serial twofold-diluted RBD and spike HexaPro protein. Neutralization assay (Neut): Purified mAb was serially diluted threefold in duplicate starting at 10 μg/mL concentration in a 96-well round-bottom plate and incubated for 1 hour at 37°C. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
Figure 1 Anti-Human SARS-CoV-2 S1 (RBD) Recombinant Antibody (V3S-0923-XY54) in SDS-PAGE.
SDS-PAGE analysis of V3S-0923-XY54 in non-reduced (Lane 1) and β-mercaptoethanol-reduced (Lane 2) conditions.
Figure 1 Anti-Human SARS-CoV-2 S1 (RBD) Recombinant Antibody (V3S-0923-XY54) in SDS-PAGE.
Figure 2 Anti-Human SARS-CoV-2 S1 (RBD) Recombinant Antibody (V3S-0923-XY54) in SEC-HPLC.
The purity of V3S-0923-XY54 was greater than 95% as determined by SEC-HPLC.
Figure 2 Anti-Human SARS-CoV-2 S1 (RBD) Recombinant Antibody (V3S-0923-XY54) in SEC-HPLC.
